<DOC>
	<DOCNO>NCT01000324</DOCNO>
	<brief_summary>This study evaluate persistence immune response HAV ( Hepatitis A Virus ) antigens HBs ( Hepatitis B surface ) antigens healthy adult previously vaccinate GlaxoSmithKline ( GSK ) Biologicals ' Twinrix™ Adult . The subject invite blood sample 16 , 17 , 18 , 19 20 year vaccination evaluate antibody persistence . For subject low circulate antibody detect , presence immune memory hepatitis A &amp; B antigens investigated administration challenge dose appropriate vaccine ( Havrix™ and/or Engerix™-B ) next plan visit . No new subject recruit study .</brief_summary>
	<brief_title>Antibody Persistence &amp; Immune Memory Healthy Adults Previously Vaccinated With Twinrix™ Adult</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>All subject must satisfy follow criterion entry longterm followup visit : Subjects investigator believe comply requirement protocol enrol study . A male female receive complete primary vaccination course primary study Hepatitis A B vaccine ( HAB ) , HAB028 ( 208127/021 ) . Written inform consent obtain subject . All subject must satisfy follow criterion entry challenge dose phase : Subjects investigator believe comply requirement protocol . A male female receive complete primary vaccination course primary study HAB028 ( 208127/021 ) . Written inform consent obtain subject . Subjects participate longterm followup ( LTFU ) phase HAB028 ( 208127/021 ) study antibody concentration cutoff last available followup timepoint . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception two month administration challenge dose . The following criterion check entry longterm followup visit . If exclusion criterion applies , subject must include study : Use investigational nonregistered product within 30 day prior blood sampling . Administration hepatitis A , hepatitis B combine hepatitis A B vaccine outside study procedure , since primary study HAB028 ( 208127/021 ) . History hepatitis A hepatitis B infection since primary study HAB028 ( 208127/021 ) . Administration hepatitis A hepatitis B immunoglobulins and/or blood product within three month prior blood sampling . The following criterion check challenge dose administer . If apply , subject must include challenge dose phase : Use investigational nonregistered product within 30 day prior study start plan use study . Administration hepatitis A , hepatitis B combine hepatitis A B vaccine last LTFU visit challenge dose visit . History hepatitis A hepatitis B infection last LTFU visit challenge dose visit . History anaphylactic reaction follow administration vaccine . History reaction hypersensitivity likely exacerbate component vaccine . Acute disease and/or fever time enrolment . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hepatitis A</keyword>
	<keyword>Hepatitis B</keyword>
</DOC>